Bordeaux, Boston, June 16, 2015 – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announcesthat it has enrolled the first patient in a major multicentric clinical protocol designed to study the medical value provided